Altimmune
ALT
180 hedge funds and large institutions have $146M invested in Altimmune in 2025 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 72 increasing their positions, 39 reducing their positions, and 34 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 39
16% more call options, than puts
Call options by funds: $26.2M | Put options by funds: $22.6M
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
2% more funds holding
Funds holding: 176 → 180 (+4)
3.2% less ownership
Funds ownership: 49.57% → 46.37% (-3.2%)
24% less capital invested
Capital invested by funds: $191M → $146M (-$45.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$5.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.11M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.94M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.94M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$6.2M |
| 3 |
Millennium Management
New York
|
-$5.59M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$5.28M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.12M |
ALT Hedge Fund Activity: Q2 2025 in Review
180 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2025, worth a combined $146M — down 24% from $191M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ALT positions and 34 closed out — a net gain of 5 holders — while 72 added to existing stakes and 39 trimmed.
The largest buyer was Caption Management, adding an estimated $5.1M. The largest seller was Ameriprise, cutting an estimated $7.2M.
- 180 institutional investors held Altimmune (ALT) as of Q2 2025, up from 176 in Q1 2025.
- Funds reported $146M of Altimmune stock for Q2 2025, down 24% quarter-over-quarter.
- 39 funds opened new Altimmune positions in Q2 2025 and 34 closed out, a net change of +5 holders.
- The largest Altimmune buyer in Q2 2025 was Caption Management, an estimated $5.1M added.
- The largest Altimmune seller in Q2 2025 was Ameriprise, an estimated $7.2M sold.
Based on aggregated 13F filings for Q2 2025.